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Sir,
Gaudreau et al.1 reported a case of group B Streptococcus (GBS)
periprosthetic joint infection (PJI) that was treated with oral peni-
cillin (300 mg once daily), but without surgical intervention. After
3 years of suppressive therapy, GBS infection relapsed, and the
isolate revealed reduced penicillin susceptibility. A similar case
was recently reported by Longtin et al.2 After 5 years of suppres-
sive therapy, the obtained isolate revealed reduced penicillin
susceptibility, although they identified different mutations from
those described in the case reported by Gaudreau et al.1 The
mutations in the ligand-binding regions of penicillin-binding
proteins probably caused the reduced susceptibility.2
We recently analysed treatment concepts and outcome in
GBS PJI,3 and we would like to comment on oral suppressive
therapy as a treatment strategy without surgical intervention.
In PJI due to GBS and other penicillin-susceptible streptococci,
controlling the infection may be particularly difficult with this
strategy. Penicillin MICs for GBS mostly range between 0.016
and 0.125 mg/L.4 An oral dose of 500 mg of penicillin optimally
reaches a peak serum concentration of 3 mg/L.5 The bone/
serum concentration ratios for penicillin are between 0.1 and
0.3.6 When extrapolating these results, 300 mg of penicillin
reaches a peak concentration of 0.18–0.54 mg/L at the infection
site. Of note, the population at risk for GBS PJI frequently has one
or more comorbidities (e.g. diabetes mellitus),3 and enteral
absorption may be reduced. For antimicrobial efficacy, a daily
time above the MIC (T.MIC) of at least 40% should be tar-
geted.7 These microbiological and pharmacological variables
should be taken into account when evaluating a treatment
concept for PJI due to penicillin-susceptible streptococci. In our
view, T.MIC ≥40% cannot be reached with 300 mg of oral peni-
cillin once daily, in particular when considering its peak level and
short half-life in serum (i.e. 30 min).5 Moreover, GBS build biofilm
and high penicillin concentrations are required for GBS eradica-
tion.8 Thus, in PJI treated with suppressive oral penicillin without
surgical intervention, a high inoculum of GBS at the infection
site is exposed to subinhibitory concentrations of penicillin. This
may lead to a selection pressure and result in the occurrence of
mutations, causing reduced susceptibility to penicillin.
In an algorithm for PJI treatment, the recommended dose and
duration of antimicrobial therapy differ for a ‘curative’ and a ‘sup-
pressive’ approach.9 In our clinics, the latter option is limited to
very few patients who are unable to undergo surgery (e.g. they
have a bad general condition or surgery is contraindicated). It is
a palliative approach, since the infection is suppressed and not
cured. Notably, suppressive therapy without surgery often goes
along with functional impairment of the joint. However, in such
cases we prefer amoxicillin because of its better bioavailability
compared with penicillin. An oral dose of 500 mg of amoxicillin
reaches a peak serum concentration of 8 mg/L and has a half-life
in serum of up to 2 h.5 Therefore, we often recommend 500–
1000 mg 8 hourly. However, the optimal amoxicillin dosing for
suppressive therapy is difficult to estimate, because the correct
balance between suppressing the infection and minimizing the
potential side effects of long-term antibiotic treatment can vary
among patients. Following the same line of reasoning, and,
hence, based on patient selection for suppressive therapy, treat-
ment duration should be as long as necessary, but as short as
possible. In PJI cases that are treated without debridement, it is
plausible to stop treatment after 9–12 months and closely
monitor the further clinical course.10 If signs of relapse occur
after discontinuation of antibiotic treatment, surgical and/or sup-
pressive treatment must be reevaluated.
Given the worrisome reports on GBS and other streptococci
with reduced penicillin susceptibility, PJI treatment strategies
should avoid a drug selection pressure over many years.
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